Aurobindo Pharma.
an Indian pharmaceutical company
- Reports this week
- 1
- Active events
- 1
- Connections
- 46
What's happening
Active this week
Earlier this month
One to three months ago
-
Indian market performance reflects global trends.Some support2 reports
-
Aurobindo Pharma operates in India.Some support1 report
-
The generic drug market is seeing significant growth, driven by Indian firms and regional markets, with major players like Aurobindo, J&J, and GSK involved.Well supported7 reports5 developments inside
-
Aurobindo Pharma's subsidiary, Eugia Pharma Specialities, faces regulatory issues in the US market.Some support4 reports
-
Market updates regarding Hindalco Industries, SIS, Aurobindo Pharma, and Bayer CropScience were reported in Mumbai starting August 1, 2026.Some support1 report1 development inside
-
SBI Securities predicts a bullish technical breakout for Aurobindo Pharma and Union Bank of India.Some support1 report
-
Power Grid Corporation of India, Biocon, and Aurobindo Pharma announced their quarterly financial results.Some support1 report
-
US-Iran tensions drive up oil prices, widening India's import bill and affecting various sectors like pharmaceuticals.Well supported18 reports4 developments inside
-
Trump announced plans for tariffs on generic drug imports while crude oil prices surged.Some support8 reports
-
Trump's tariff plan is pressuring Indian pharmaceutical companies Aurobindo Pharma and Cipla to localize production.Well supported13 reports2 developments inside
-
Trump's tariff plan pressured pharmaceutical stocks, affecting companies including Aurobindo Pharma, Cipla, Alkem Laboratories, and Torrent Pharmaceuticals.Some support11 reports
-
Maruti Suzuki and Aurobindo Pharma face price hikes due to input costs, while Aurobindo establishes a biosimilars facility in Hyderabad and receives ANVISA approval.Some support1 report
Gone quiet
No new reports in 90+ days-
A fund increased its conviction in both Tata Communications and Aurobindo Pharma stocks on July 8, 2026.Some support1 report
-
Stocks across various sectors are showing strong buying interest and hitting 52-week highs, reflecting positive domestic market trends.Some support2 reports
-
Multiple corporate actions, including a settlement with NMC Health PLC, fintech partnerships with Canara Bank, and battery cell agreements.Some support1 report
-
Aurobindo Pharma, Zensar Technologies, Torrent Pharmaceuticals, and Aadhar Housing Finance showed strong upward momentum on July 1, 2026.Some support1 report
-
Aurobindo Pharma is experiencing targets suggesting significant revenue growth and market expansion.Some support2 reports
-
A market report lists several Indian companies, including Maruti Suzuki and Aurobindo Pharma, as laggards or movers following a global oil price drop.Some support2 reports
-
Aurobindo Pharma, which has a facility in Telangana, owns Eugia Pharma Specialities.Some support1 report
-
Solar projects are being secured under state government schemes, while an Iran-US agreement boosts investor sentiment in India. Meanwhile, an Indian pharma company faces USFDA inspection issues.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Aurobindo Pharma this week
News at the entities that move Aurobindo Pharma most-
Brent OperationalShort-haul supplies are pushing Brent crude to record premiums while high freight costs widen spot discounts for African crude.Moves Aurobindo Pharma
-
Donald Trump OperationalTrump allegedly ignored Graham's sanctions bill, slowed Starlink connections, and lifted sanctions to help Putin.Moves Aurobindo Pharma
-
European Medicines Agency StructuralGlenn attended a congress in Amsterdam and participated in a panel with an official from the European Medicines Agency.Moves Aurobindo Pharma
-
FDA StructuralNeurogene Inc. developed a gene therapy for Rett syndrome and received FDA agreement for a registrational trial design.Moves Aurobindo Pharma
-
United States Food and Drug Administration StructuralDr. Reddy's Laboratories' manufacturing facility in Visakhapatnam underwent a USFDA pre-approval inspection.Moves Aurobindo Pharma
-
Europe StructuralAn iceberg threatens the European coast from the Arctic, contrasting with the President's indifference and military response.Moves Aurobindo Pharma
Connections
The 25 strongest of 46, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Donald Trump Operational
Trump's proposed tariff policies are actively pressuring Aurobindo Pharma's market viability and generic drug imports.
-
FDA Structural
Aurobindo Pharma is currently undergoing inspections by the FDA regarding manufacturing compliance.
-
Nimmagadda Prasad Transactional
Aurobindo Pharma made substantial investments into companies associated with Nimmagadda Prasad.
-
United States Food and Drug Administration Structural
US FDA conducts inspections of Aurobindo Pharma subsidiaries as part of regulatory oversight.
-
Europe Structural
The European market provides necessary conditions and revenue support for Aurobindo Pharma's operations.
-
Brent Operational
Brent crude oil price movements contribute to market uncertainty, which subsequently affects the sentiment and operational costs of pharmaceutical companies like Aurobindo.
-
Cipla Operational
The two companies are direct competitors facing shared market pressure due to US tariffs.
-
Telangana Structural
Aurobindo Pharma operates a facility in Telangana, which is subject to state regulations and international oversight.
Show all 25 connections
-
Bajaj Life Insurance Operational
The available evidence suggests the two companies are actively interacting in the market, though specific details are missing.
-
Kalyan Jewellers Mentioned together
The entities are co-mentioned as midcap movers in the market.
-
MSD Transactional
MSD and Aurobindo Pharma entered a voluntary licensing agreement for the generic drug alimatravir.
-
India Shared context
Aurobindo Pharma operates as a company within the Indian market structure.
-
Coal India Shared context
The relationship is based on shared market context, specifically the pressures faced by Indian equities in September.
-
European Medicines Agency Structural
The European Medicines Agency has certified a facility belonging to Aurobindo Pharma.
-
Hyderabad Shared context
Aurobindo Pharma operates its biosimilars manufacturing facility and headquarters within the geographical boundaries of Hyderabad.
-
Federal Bank Mentioned together
Both companies were mentioned in the context of stocks registering fresh life-time highs in August 2026.
-
Tata Communications Mentioned together
Both stocks are noted by a fund for increased conviction.
-
Acadia Pharmaceuticals Operational
Acadia Pharmaceuticals and Aurobindo Pharma are engaged in legal competition regarding intellectual property rights.
-
Raleigh Shared context
Aurobindo Pharma operates a plant in Raleigh that is undergoing regulatory review.
-
Zensar Technologies Mentioned together
The entities were co-mentioned in articles noting they both experienced strong upward market momentum.
-
Mumbai Shared context
The company is mentioned in market updates related to the city's operational context.
-
SBI Securities Mentioned together
Both SBI Securities and Aurobindo Pharma are currently trading at record levels with strong market momentum.
-
Macquarie Transactional
Macquarie initiated a Neutral rating on Aurobindo Pharma.
-
CSR Transactional
The two entities engaged in a charitable transaction, donating Rs 10 crore towards school meals.
-
Federal Trade Commission Mentioned together
No evidence was provided linking Aurobindo Pharma and the Federal Trade Commission.
History
Events by the month they beganOctober 2026
2 eventsSeptember 2026
2 eventsAugust 2026
4 events- Aurobindo Pharma's subsidiary, Eugia Pharma Specialities, faces regulatory issues in the US market.
- Market updates regarding Hindalco Industries, SIS, Aurobindo Pharma, and Bayer CropScience were reported in Mumbai starting August 1, 2026.
- SBI Securities predicts a bullish technical breakout for Aurobindo Pharma and Union Bank of India.
- Power Grid Corporation of India, Biocon, and Aurobindo Pharma announced their quarterly financial results.
Show 2 earlier months
July 2026
10 events- MSD and Aurobindo Pharma signed a voluntary licensing agreement for generic alimatravir.
- US-Iran tensions drive up oil prices, widening India's import bill and affecting various sectors like pharmaceuticals.
- Trump announced plans for tariffs on generic drug imports while crude oil prices surged.
- Trump's tariff plan is pressuring Indian pharmaceutical companies Aurobindo Pharma and Cipla to localize production.
- Trump's tariff plan pressured pharmaceutical stocks, affecting companies including Aurobindo Pharma, Cipla, Alkem Laboratories, and Torrent Pharmaceuticals.
- Maruti Suzuki and Aurobindo Pharma face price hikes due to input costs, while Aurobindo establishes a biosimilars facility in Hyderabad and receives ANVISA approval.
- A fund increased its conviction in both Tata Communications and Aurobindo Pharma stocks on July 8, 2026.
- Stocks across various sectors are showing strong buying interest and hitting 52-week highs, reflecting positive domestic market trends.
- Multiple corporate actions, including a settlement with NMC Health PLC, fintech partnerships with Canara Bank, and battery cell agreements.
- Aurobindo Pharma, Zensar Technologies, Torrent Pharmaceuticals, and Aadhar Housing Finance showed strong upward momentum on July 1, 2026.
June 2026
5 events- The generic drug market is seeing significant growth, driven by Indian firms and regional markets, with major players like Aurobindo, J&J, and GSK involved.
- Aurobindo Pharma is experiencing targets suggesting significant revenue growth and market expansion.
- A market report lists several Indian companies, including Maruti Suzuki and Aurobindo Pharma, as laggards or movers following a global oil price drop.
- Aurobindo Pharma, which has a facility in Telangana, owns Eugia Pharma Specialities.
- Solar projects are being secured under state government schemes, while an Iran-US agreement boosts investor sentiment in India. Meanwhile, an Indian pharma company faces USFDA inspection issues.